Stock SILO SILO PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Silo Pharma, Inc.

Equities

SILO

US82711P2011

Delayed Nasdaq
Other stock markets
 19:01:47 17/05/2024 BST 		5-day change 1st Jan Change
1.9 USD +1.06% Intraday chart for Silo Pharma, Inc. +13.10% +31.94%
04-23 Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment CI
04-10 Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment
CI
Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University
MT
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.
CI
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.
CI
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.
CI
Silo Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Silo Pharma, Inc. Exercises Option for Exclusive License Agreement for First-In-Class PTSD and Stress-Induced Anxiety Therapeutic
CI
Silo Pharma, Inc. Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
CI
Silo Pharma?s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
CI
Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
CI
Silo Pharma Announces Positive Results in Alzheimer?s Disease Study
CI
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.
CI
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
CI
Silo Pharma, Partner Receive Regulatory Approval to Develop Ketamine Implant for Fibromyalgia Treatment
MT
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
CI
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.
CI
Silo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Silo Pharma, Inc. to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
CI
Silo Pharma?s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
CI
Silo Pharma, Inc. Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug Application with FDA
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SILO Stock
  4. News Silo Pharma, Inc.
  5. Highlights